首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | 97 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | BDNF |
| Uniprot No | P23560 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 129-247aa |
| 氨基酸序列 | MHSDPARRGELSVCDSISEWVTAADKKTAVDMSGGTVTVLEKVPVSKGQL KQYFYETKCNPMGYTKEGCRGIDKRHWNSQCRTTQSYVRALTMDSKKRIG WRFIRIDTSCVCTLTIKRGR |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于BDNF重组蛋白的参考文献摘要概括：
---
1. **文献名称**：*Production and purification of recombinant BDNF for neuronal cell culture applications*
**作者**：Mowla, S. J., et al.
**摘要**：该研究描述了通过大肠杆菌表达系统高效生产重组人BDNF蛋白的方法，采用His标签纯化技术获得高纯度蛋白，并验证了其在促进神经元存活和轴突生长中的生物活性。
---
2. **文献名称**：*BDNF-based therapeutics: A new era in neurological disorder treatment*
**作者**：Binder, D. K., & Scharfman, H. E.
**摘要**：综述了重组BDNF在帕金森病、抑郁症等神经系统疾病中的治疗潜力，重点讨论了其通过基因递送或缓释载体克服血脑屏障限制的策略，并比较了不同重组表达系统的优缺点。
---
3. **文献名称**：*Trk receptor signaling and BDNF function in synaptic plasticity*
**作者**：Huang, E. J., & Reichardt, L. F.
**摘要**：通过体外实验证明重组BDNF蛋白激活TrkB受体后触发MAPK/PI3K信号通路，增强海马神经元突触可塑性，为神经退行性疾病的分子机制提供了直接证据。
---
4. **文献名称**：*Recombinant BDNF rescues Alzheimer’s disease model mice via hippocampal neurogenesis*
**作者**：Nagahara, A. H., & Tuszynski, M. H.
**摘要**：利用腺病毒载体递送重组BDNF至阿尔茨海默病模型小鼠海马区，结果显示其显著改善认知功能并促进新生神经元存活，为临床转化提供了动物实验依据。
---
*注：以上文献标题及作者为示例性质，具体内容需根据实际论文调整。建议通过PubMed或Google Scholar检索最新研究获取准确信息。*
Brain-derived neurotrophic factor (BDNF) is a key neurotrophin involved in neuronal survival, synaptic plasticity, and cognitive function. It binds to tropomyosin receptor kinase B (TrkB) and the p75 neurotrophin receptor, activating signaling pathways critical for neurodevelopment and adaptive brain processes. Dysregulation of BDNF is linked to neurodegenerative diseases (e.g., Alzheimer’s), psychiatric disorders (e.g., depression), and impaired learning.
Recombinant BDNF protein, produced via genetic engineering in bacterial (e.g., *E. coli*) or eukaryotic (e.g., mammalian or insect cells) systems, mimics native BDNF’s biological activity. Its production typically involves codon optimization, purification steps (affinity chromatography), and validation through cell-based assays or animal models. Unlike endogenous BDNF, recombinant forms enable standardized dosing and scalable therapeutic applications.
Therapeutic research focuses on BDNF’s potential to counteract neurodegeneration, enhance neuroregeneration, or improve mood disorders. However, challenges persist: short half-life, poor blood-brain barrier (BBB) penetration, and off-target effects. Strategies like fusion proteins, nanoparticle delivery, or gene therapy (viral vectors encoding BDNF) aim to overcome these limitations.
Clinically, recombinant BDNF has shown mixed outcomes. While early trials for ALS and peripheral neuropathy yielded limited efficacy, newer approaches targeting localized delivery (intranasal, intrathecal) or combinatorial therapies show promise. In research, it remains a vital tool for studying neurotrophic signaling and disease mechanisms.
Advances in protein engineering (e.g., PEGylation for stability) and biomaterials (hydrogels for sustained release) continue to refine its therapeutic profile. Despite hurdles, recombinant BDNF represents a cornerstone in translational neuroscience, bridging molecular insights with potential treatments for brain disorders.
×
